0001193125-22-172960.txt : 20220613 0001193125-22-172960.hdr.sgml : 20220613 20220613163403 ACCESSION NUMBER: 0001193125-22-172960 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220609 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220613 DATE AS OF CHANGE: 20220613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 221012092 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d366008d8k.htm 8-K 8-K
false 0001840574 0001840574 2022-06-09 2022-06-09














Date of report (Date of earliest event reported): June 9, 2022



Verve Therapeutics, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-40489   82-4800132
(State or Other Jurisdiction
of Incorporation)
File Number)
  (IRS Employer
Identification No.)

500 Technology Square, Suite 901

Cambridge, Massachusetts


(Address of principal executive offices, including zip code)

(617) 603-0070

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange
on which registered

Common stock, $0.001 par value per share   VERV   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 9, 2022, the board of directors (the “Board”) of Verve Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Alexander “Bo” Cumbo as a member of the Board and as a member of the Compensation Committee of the Board, effective as of June 9, 2022. Mr. Cumbo was designated as a Class II director with a term expiring at the 2023 annual meeting of the stockholders of the Company and thereafter until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Mr. Cumbo is “independent” as contemplated by the Nasdaq Stock Market and other governing laws and applicable regulations. The election of Mr. Cumbo brings the size of the Board to seven members.

Mr. Cumbo, age 51, has served as the President and Chief Executive Officer of AavantiBio, Inc., a gene therapy company, since October 2020. From January 2013 to October 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., a leader in precision genetic medicine for rare diseases, ultimately serving as Executive Vice President, Chief Commercial Officer. From 2011 to 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education for Vertex Pharmaceuticals Incorporated, a global biotechnology company, launching Incivek, a treatment for hepatitis C, and from 2010 to 2011, he served as Area Director for Vertex. Prior to Vertex, Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV, and cardiovascular franchises at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Cumbo previously served on the board of RA Pharmaceuticals, Inc., a clinical stage biopharmaceutical company acquired by UCB, Brussels, from November 2018 to April 2020. Mr. Cumbo received his Bachelor of Science in Laboratory Technology from Auburn University.

There are no arrangements or understandings between Mr. Cumbo and any other person pursuant to which he was elected as a director. There are no transactions in which Mr. Cumbo has an interest requiring disclosure under Item 404(a) of Regulation S-K of the Securities Act of 1933, as amended.

Mr. Cumbo will be compensated in the same manner as the Company’s other non-employee directors. Information concerning the current compensation of the Company’s directors is set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 29, 2022. Accordingly, Mr. Cumbo received, upon his election to the Board, an option to purchase 31,000 shares of common stock of the Company at an exercise price of $14.04 per share, the closing price per share of the Company’s common stock on the Nasdaq Global Select Market on the effective date of Mr. Cumbo’s election.

In connection with his election, Mr. Cumbo has entered into the Company’s standard form of Indemnification Agreement, a copy of which was filed as Exhibit 10.17 to the Company’s Registration Statement on Form S-1 (File No. 333-256608) filed with the SEC on May 28, 2021. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Mr. Cumbo for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.

Item 5.07

Submission of Matters to a Vote of Security Holders

The Company held its Annual Meeting of Stockholders on June 9, 2022 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the two proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement, filed with the SEC on April 29, 2022. The final voting results are set forth below.

Proposal 1 – Election of Class I Directors

The stockholders of the Company elected John Evans and Krishna Yeshwant, M.D. to serve as Class I directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2025 and until each of their successors has been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class I directors were as follows:








John Evans   30,009,983   9,111,871   8,241,140
Krishna Yeshwant, M.D.   34,087,840   5,034,015   8,241,140

Proposal 2 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders’ vote with respect to such ratification were as follows:








42,665,206   4,205,067   492,722

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Verve Therapeutics, Inc.
Date: June 13, 2022     By:  

/s/ Andrew D. Ashe

      Name: Andrew D. Ashe
      Title: President, Chief Operating Officer and
General Counsel
EX-101.SCH 2 verv-20220609.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 verv-20220609_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 verv-20220609_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Jun. 09, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001840574
Document Type 8-K
Document Period End Date Jun. 09, 2022
Entity Registrant Name Verve Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40489
Entity Tax Identification Number 82-4800132
Entity Address, Address Line One 500 Technology Square
Entity Address, Address Line Two Suite 901
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 603-0070
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, $0.001 par value per share
Trading Symbol VERV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d366008d8k_htm.xml IDEA: XBRL DOCUMENT 0001840574 2022-06-09 2022-06-09 false 0001840574 8-K 2022-06-09 Verve Therapeutics, Inc. DE 001-40489 82-4800132 500 Technology Square Suite 901 Cambridge MA 02139 (617) 603-0070 false false false false Common stock, $0.001 par value per share VERV NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d366008d8k.htm verv-20220609.xsd verv-20220609_lab.xml verv-20220609_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d366008d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d366008d8k.htm" ] }, "labelLink": { "local": [ "verv-20220609_lab.xml" ] }, "presentationLink": { "local": [ "verv-20220609_pre.xml" ] }, "schema": { "local": [ "verv-20220609.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "verv", "nsuri": "http://www.vervetx.com/20220609", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d366008d8k.htm", "contextRef": "duration_2022-06-09_to_2022-06-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d366008d8k.htm", "contextRef": "duration_2022-06-09_to_2022-06-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vervetx.com//20220609/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-22-172960-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-172960-xbrl.zip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